Additionally, T-ALL patients with higher CD6/CD3G expression had a favorable OS, while TCL patients with higher CD6/CD3E, CD6/CD3D, CD6/CD247, CD6/CD8, and CD6/CD8B (HR < 1, P < 0.07) had favorable outcomes (Figure 3(b)). Here, CD3D is linked to acute lymphoblastic leukemia.